Summer 2026

Trader Intern

Maven Securities

Maven Securities

201-500 employees

Proprietary-capital multi-strategy trading and market making

No salary listed

London, UK

In Person

Internship includes 3 weeks in London office followed by 6 weeks in Amsterdam.

Category
Finance & Banking (1)
Requirements
  • You must be in your penultimate year of university to be eligible for this position.
  • Strong numeracy and a good understanding of probability and statistics.
  • Competitive nature with a curiosity to learn and a keen interest in financial markets.
  • Excellent analytical skills with the ability to solve problems creatively.
  • Good communication skills and drive to work collaboratively.
  • A penultimate year student with a bachelor's degree or higher in a quantitative field.
Responsibilities
  • Complete a nine-week training programme in Options Market Making run by our traders, including trading simulation, project work and programming courses.
  • Spend the first three weeks in our London office for a fast-paced, interactive introduction to Trading, before returning to Amsterdam for the remaining six weeks of the programme.
  • Attend regular social events and gain insight into the work of our market making desks.
  • Be considered for a place on our 2027 Amsterdam Graduate Trader Programme.

Maven Securities trades and provides market liquidity across global financial markets using its own capital. It combines fundamental and quantitative methods to find trading opportunities and to execute trades efficiently from front office to settlements. The firm differentiates itself by using exclusively proprietary capital, strong risk controls, and a focus on technology to improve execution. Its goal is to earn sustainable profits while keeping markets liquid for institutional clients and other traders.

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $1.30M MBX Biosciences investment captures biotech Phase 3 momentum.
  • MBX 4291 Phase 1 obesity data drives volatility for quantitative strategies.
  • $3.9B AUM enables scaling tech-driven liquidity provision globally.

What critics are saying

  • MBX canvuparatide Phase 3 failure erases $1.30M stake in 12 months.
  • Novo Nordisk CagriSema eclipses MBX obesity pipeline in 18 months.
  • BlackRock 4.8% crowding triggers MBX drawdowns in 3 months.

What makes Maven Securities unique

  • Maven Securities trades proprietary capital exclusively across global markets.
  • Integrates computer learning and processing power for trading operations.
  • Employs multi-strategy fundamental and quantitative market-making approaches.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401K Scheme

25 Days Annual Leave plus public holidays

Healthcare, Dental & Vision

Employee Volunteering Opportunities

Annual Discretionary Bonus

Company News

MarketBeat
Aug 21st, 2025
Maven Securities LTD Invests $4 Million in StandardAero, Inc. $SARO

Maven Securities LTD has invested approximately $4 million in StandardAero, acquiring a stake of 150,000 shares as of the first quarter of 2023.

ETF Daily News
Apr 2nd, 2025
Corebridge Financial Inc. Has $2.37 Million Stock Position in Sotera Health (NASDAQ:SHC)

Maven Securities LTD acquired a new stake in Sotera Health in the 3rd quarter valued at approximately $1,670,000.

MarketBeat
Mar 2nd, 2025
Rithm Capital Corp. (NYSE:RITM) Shares Sold by Y Intercept Hong Kong Ltd

Soros Fund Management LLC acquired a new stake in Rithm Capital in the 3rd quarter valued at about $23,835,000.

MarketBeat
Jan 19th, 2025
Rithm Capital Corp. (NYSE:RITM) Receives $12.94 Consensus Price Target from Brokerages

Finally, Maven Securities LTD purchased a new stake in Rithm Capital in the 3rd quarter worth about $11,350,000.

ETF Daily News
Dec 18th, 2024
Wellington Management Group LLP Cuts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

Maven Securities LTD purchased a new stake in Wave Life Sciences in the third quarter worth $6,970,000.